Latest news with #Quantumzyme
Associated Press
28-04-2025
- Business
- Associated Press
Quantumzyme Highlights Benefits and Commercialization Opportunities of Pending Breakthrough Green Chemistry Patent
SAN DIEGO, CA - April 28, 2025 ( NEWMEDIAWIRE ) - Quantumzyme Corp. (OTC: QTZM), a biotechnology company leveraging computational enzyme engineering, is pleased to announce the key benefits and commercialization avenues of its soon to be published patented enzymatic process for sustainable ibuprofen production. This innovation not only strengthens Quantumzyme's leadership in green chemistry but also positions the company to capitalize on the global shift toward cleaner, more efficient manufacturing technologies. The process utilizes a specially engineered enzyme to streamline ibuprofen production, significantly reducing the use of harsh chemicals, solvents, and energy. By replacing traditional multi-step chemical synthesis with a selective biocatalytic transformation, Quantumzyme's method offers both environmental and economic advantages. Key Benefits of the Breakthrough Process: Quantumzyme plans to offer this soon to be patented process across multiple channels: 'Our enzymatic ibuprofen process exemplifies how cutting-edge science can address real-world industrial challenges,' stated Naveen Kulkarni, CEO of Quantumzyme. 'Through strategic commercialization, we aim to help manufacturers achieve regulatory compliance, meet ESG goals, and reduce costs - all while making chemistry greener.' This breakthrough directly resonates with the scientific momentum sparked by the 2024 Nobel Prize in Chemistry, awarded for advancements in computational enzyme design and protein structure prediction. Like Nobel laureates David Baker, Demis Hassabis, and John Jumper, Quantumzyme leverages artificial intelligence and protein engineering to revolutionize industrial chemistry - delivering sustainable, scalable solutions for the pharmaceutical sector. By combining green chemistry, computational design, and strategic commercialization, Quantumzyme's goal is to set new standards for the future of sustainable pharmaceutical production. For the most current information and updates, please visit our website at About Quantumzyme Corp. Quantumzyme Corp. is a pioneering biotransformation company revolutionizing chemical processes through sustainable, enzyme-based solutions. Specializing in green chemistry, it harnesses quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to design high-performance biocatalysts that enhance efficiency, reduce waste, and minimize environmental impact. By integrating computational modeling with wet-lab validation, Quantumzyme delivers scalable, cost-effective biocatalysis solutions that improve industrial sustainability. Offering end-to-end enzyme development services - from discovery and engineering to process optimization and scale-up - Quantumzyme empowers its partners to adopt greener, more efficient production methods. Committed to sustainability and innovation, the company envisions a future where biotechnology drives global solutions for climate change, pollution, and resource efficiency, making eco-friendly biocatalysis the industry standard. Disclaimer The information contained in this press release is provided by Quantumzyme Corp. ('Quantumzyme') for general informational purposes only. This release may include forward-looking statements that reflect Quantumzyme's current expectations, estimates, projections, and assumptions about future events, business performance, market conditions, or technological developments. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. Forward-looking statements are based on management's beliefs and assumptions as of the date of this press release and are subject to change without notice. Quantumzyme makes no representations or warranties, express or implied, regarding the accuracy, completeness, or reliability of the information contained herein. The company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future developments, or changes in expectations, except as required by applicable law. Past performance should not be taken as an indicator of future results, and readers should not place undue reliance on any projections or expectations presented in this release. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it provide financial, investment, or legal advice. Any references to market trends, scientific advancements, or industry insights are provided for contextual purposes only and should not be interpreted as endorsements, guarantees, or definitive predictions of future developments. Readers and investors are encouraged to conduct their own due diligence and seek independent professional advice before making any investment or business decisions related to Quantumzyme or its affiliates. Media Contact: Naveen Kulkarni Chief Executive Officer Quantumzyme Corp. 15656 Bernardo Center Drive, Suite 801 San Diego, CA 92127 Phone: +1 (858) 203-0312 Email: [email protected] Website: View the original release on
Associated Press
23-04-2025
- Business
- Associated Press
Quantumzyme Anticipates Publication of Transformative Patent for Enzymatic Ibuprofen Manufacturing
SAN DIEGO, CA - April 23, 2025 ( NEWMEDIAWIRE ) - Quantumzyme Corp. (OTC: QTZM), a biotechnology company leveraging computational enzyme engineering, is pleased to announce the upcoming publication of its patent for an innovative enzymatic method to manufacture ibuprofen. Expected to be published in the coming months, the patent details a unique approach using a modified polypeptide that supports a more sustainable and efficient alternative to conventional production methods. This enzymatic method represents a significant step forward in pharmaceutical manufacturing, offering a cleaner and more streamlined route to ibuprofen - one of the most commonly used nonsteroidal anti-inflammatory drugs (NSAIDs). By harnessing a specialized enzyme, the process reduces dependence on harsh chemicals and minimizes reaction steps, leading to better yields and a smaller environmental footprint. 'We're looking forward to the publication of this patent, which reflects our continued focus on enabling greener solutions for complex chemical challenges,' said Naveen Kulkarni, CEO of Quantumzyme. 'It's a clear example of how enzyme-driven processes can be applied to improve efficiency and sustainability in pharmaceutical manufacturing.' The publication will further solidify Quantumzyme's position as a driving force in enzyme-based technology for the pharmaceutical sector. The company anticipates new licensing opportunities and a broader industry impact as it builds on its growing intellectual property portfolio. 'We are proud of the science behind this patent,' added Kulkarni. 'It underscores the potential of enzyme innovation to reimagine essential manufacturing processes in a more responsible and scalable way.' As the industry continues shifting toward environmentally conscious practices, Quantumzyme's biocatalytic method positions itself as a compelling solution for future-ready API production. For the most current information and updates, please visit our website at About Quantumzyme Corp. Quantumzyme Corp. is a pioneering biotransformation company revolutionizing chemical processes through sustainable, enzyme-based solutions. Specializing in green chemistry, it harnesses quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to design high-performance biocatalysts that enhance efficiency, reduce waste, and minimize environmental impact. By integrating computational modeling with wet-lab validation, Quantumzyme delivers scalable, cost-effective biocatalysis solutions that improve industrial sustainability. Offering end-to-end enzyme development services - from discovery and engineering to process optimization and scale-up - Quantumzyme empowers its partners to adopt greener, more efficient production methods. Committed to sustainability and innovation, the company envisions a future where biotechnology drives global solutions for climate change, pollution, and resource efficiency, making eco-friendly biocatalysis the industry standard. Disclaimer The information contained in this press release is provided by Quantumzyme Corp. ('Quantumzyme') for general informational purposes only. This release may include forward-looking statements that reflect Quantumzyme's current expectations, estimates, projections, and assumptions about future events, business performance, market conditions, or technological developments. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. Forward-looking statements are based on management's beliefs and assumptions as of the date of this press release and are subject to change without notice. Quantumzyme makes no representations or warranties, express or implied, regarding the accuracy, completeness, or reliability of the information contained herein. The company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future developments, or changes in expectations, except as required by applicable law. Past performance should not be taken as an indicator of future results, and readers should not place undue reliance on any projections or expectations presented in this release. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it provide financial, investment, or legal advice. Any references to market trends, scientific advancements, or industry insights are provided for contextual purposes only and should not be interpreted as endorsements, guarantees, or definitive predictions of future developments. Readers and investors are encouraged to conduct their own due diligence and seek independent professional advice before making any investment or business decisions related to Quantumzyme or its affiliates. Media Contact: Naveen Kulkarni Chief Executive Officer Quantumzyme Corp. 15656 Bernardo Center Drive, Suite 801 San Diego, CA 92127 Phone: +1 (858) 203-0312 Email: [email protected] Website: View the original release on
Associated Press
16-04-2025
- Business
- Associated Press
Quantumzyme Highlights Enzyme Engineering Platform and Ongoing Work in Sustainable Ibuprofen Synthesis
SAN DIEGO, CA - April 16, 2025 ( NEWMEDIAWIRE ) - Quantumzyme Corp. (OTC: QTZM), a biotechnology company leveraging computational enzyme engineering, is providing insight into the company's enzymatic design capabilities and current areas of research-particularly in the field of sustainable pharmaceutical manufacturing. As part of its green chemistry initiatives, Quantumzyme has been evaluating enzyme-based methods to reduce the environmental footprint of common small molecule drug production. One area of focus has been the development of an enzyme-driven approach to ibuprofen synthesis. Ibuprofen, a widely used anti-inflammatory and pain relief medication, is typically produced through multi-step chemical processes that involve hazardous reagents and generate significant chemical waste. 'At Quantumzyme, we're exploring how computationally designed enzymes can be used to reimagine traditional chemical processes,' stated Naveen Kulkarni, CEO of Quantumzyme. 'While our work on ibuprofen synthesis continues to evolve, it illustrates the potential of enzyme catalysis to reduce complexity and environmental impact in pharmaceutical manufacturing.' The company's enzyme discovery efforts center on its proprietary in silico platform, which integrates structural modeling, molecular docking, and virtual screening to identify enzymes with high specificity and stability for industrially relevant reactions. In the case of ibuprofen, Quantumzyme's team screened 22 candidate enzymes and identified a promising variant- bcPADH from Burkholderia cenocepacia- capable of converting a key intermediate (ibuprofen aldehyde) into the final active pharmaceutical ingredient under lab conditions. By using bacterial systems to express and optimize this enzyme, the company has been able to achieve high conversion efficiency and purity, under safer, low-energy conditions. Importantly, this method avoids the use of harsh substances such as hydrofluoric acid, carbon monoxide, and pyrophoric metals commonly found in traditional synthesis routes. While Quantumzyme's current research around ibuprofen is one application, the platform is being developed to support a wide range of use cases across pharmaceuticals, specialty chemicals, agrochemicals, and biofuels. The company's strategy focuses on applying green chemistry principles to reduce hazardous inputs, minimize waste, and improve process efficiency across sectors. 'This is about more than one molecule,' added Kulkarni. 'We're building a platform that can be applied broadly- wherever sustainable, precise biocatalysis can offer value over conventional chemistry.' Quantumzyme continues to optimize its enzyme systems and evaluate potential commercial pathways for future deployment. We are presently assessing scale-up feasibility and industry integration for our enzyme-enabled solutions. For the most current information and updates, please visit our website at About Quantumzyme Corp. Quantumzyme Corp. is a pioneering biotransformation company revolutionizing chemical processes through sustainable, enzyme-based solutions. Specializing in green chemistry, it harnesses quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to design high-performance biocatalysts that enhance efficiency, reduce waste, and minimize environmental impact. By integrating computational modeling with wet-lab validation, Quantumzyme delivers scalable, cost-effective biocatalysis solutions that improve industrial sustainability. Offering end-to-end enzyme development services- from discovery and engineering to process optimization and scale-up—Quantumzyme empowers its partners to adopt greener, more efficient production methods. Committed to sustainability and innovation, the company envisions a future where biotechnology drives global solutions for climate change, pollution, and resource efficiency, making eco-friendly biocatalysis the industry standard. Disclaimer The information contained in this press release is provided by Quantumzyme Corp. ('Quantumzyme') for general informational purposes only. This release may include forward-looking statements that reflect Quantumzyme's current expectations, estimates, projections, and assumptions about future events, business performance, market conditions, or technological developments. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. Forward-looking statements are based on management's beliefs and assumptions as of the date of this press release and are subject to change without notice. Quantumzyme makes no representations or warranties, express or implied, regarding the accuracy, completeness, or reliability of the information contained herein. The company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future developments, or changes in expectations, except as required by applicable law. Past performance should not be taken as an indicator of future results, and readers should not place undue reliance on any projections or expectations presented in this release. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it provide financial, investment, or legal advice. Any references to market trends, scientific advancements, or industry insights are provided for contextual purposes only and should not be interpreted as endorsements, guarantees, or definitive predictions of future developments. Readers and investors are encouraged to conduct their own due diligence and seek independent professional advice before making any investment or business decisions related to Quantumzyme or its affiliates. Media Contact: Naveen Kulkarni Chief Executive Officer Quantumzyme Corp. 15656 Bernardo Center Drive, Suite 801 San Diego, CA 92127 Phone: +1 (858) 203-0312 Email: [email protected] Website: View the original release on
Associated Press
08-04-2025
- Business
- Associated Press
Quantumzyme Introduces Manu Bharath Khareedhi as Independent Director, Looks to Strengthen Strategic Growth and Innovation
NEWMEDIAWIRE) - Quantumzyme Corp. (OTC:QTZM), a pioneering biotechnology company specializing in computational enzyme engineering, is pleased to introduce Manu Bharath Khareedhi as an Independent Member of its Board of Directors. With extensive experience in biotechnology, business strategy, and global market expansion, Khareedhi's leadership will be instrumental in accelerating Quantumzyme's growth and enhancing its impact in the biocatalysis industry. Manu Bharath Khareedhi is a seasoned executive with a proven track record in life sciences, biopharmaceuticals, and sustainable manufacturing. Throughout his career, he has been at the forefront of business transformation, strategic partnerships, and operational excellence. With deep expertise in biotechnology commercialization, he has played a key role in scaling innovative technologies into globally competitive solutions. Khareedhi has successfully led multiple biotech enterprises, guiding them through product development, regulatory landscapes, and market expansion. His ability to identify growth opportunities, drive business efficiency, and foster strategic collaborations makes him a valuable addition to Quantumzyme's Board. As Independent Director, Manu Bharath Khareedhi will play a pivotal role in guiding Quantumzyme's long-term strategy, focusing on: Expanding global partnerships to drive the adoption of sustainable enzymatic solutions. Enhancing commercialization strategies to bring Quantumzyme's cutting-edge enzyme technologies to market. Strengthening corporate governance and operational excellence to scale up the company's innovations. Supporting R&D advancements in AI-driven enzyme engineering for pharmaceuticals, chemicals, and renewable energy. Accelerating Quantumzyme's growth trajectory by aligning business strategy with industry trends and emerging opportunities. 'I am excited to join Quantumzyme as an Independent Director at such a transformative time in the industry,' stated Manu Bharath Khareedhi. 'Quantumzyme is at the forefront of next-generation enzyme engineering, redefining how industries approach sustainable manufacturing. I look forward to working with the leadership team to drive innovation, expand market opportunities, and create lasting impact in the biotechnology space.' For the most current information and updates, please visit our website at About Quantumzyme Corp. Quantumzyme Corp. is a pioneering biotransformation company revolutionizing chemical processes through sustainable, enzyme-based solutions. Specializing in green chemistry, it harnesses quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to design high-performance biocatalysts that enhance efficiency, reduce waste, and minimize environmental impact. By integrating computational modeling with wet-lab validation, Quantumzyme delivers scalable, cost-effective biocatalysis solutions that improve industrial sustainability. Offering end-to-end enzyme development services—from discovery and engineering to process optimization and scale-up—Quantumzyme empowers its partners to adopt greener, more efficient production methods. Committed to sustainability and innovation, the company envisions a future where biotechnology drives global solutions for climate change, pollution, and resource efficiency, making eco-friendly biocatalysis the industry standard. Disclaimer The information contained in this press release is provided by Quantumzyme Corp. ('Quantumzyme') for general informational purposes only. This release may include forward-looking statements that reflect Quantumzyme's current expectations, estimates, projections, and assumptions about future events, business performance, market conditions, or technological developments. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. Forward-looking statements are based on management's beliefs and assumptions as of the date of this press release and are subject to change without notice. Quantumzyme makes no representations or warranties, express or implied, regarding the accuracy, completeness, or reliability of the information contained herein. The company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future developments, or changes in expectations, except as required by applicable law. Past performance should not be taken as an indicator of future results, and readers should not place undue reliance on any projections or expectations presented in this release. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it provide financial, investment, or legal advice. Any references to market trends, scientific advancements, or industry insights are provided for contextual purposes only and should not be interpreted as endorsements, guarantees, or definitive predictions of future developments. Readers and investors are encouraged to conduct their own due diligence and seek independent professional advice before making any investment or business decisions related to Quantumzyme or its affiliates. Media Contact: Naveen Kulkarni Chief Executive Officer Quantumzyme Corp. 15656 Bernardo Center Drive, Suite 801 San Diego, CA 92127
Associated Press
04-04-2025
- Business
- Associated Press
Quantumzyme Signs MOU With Zummit Africa to Establish a Centre of Excellence in AI for Green Chemistry
NEWMEDIAWIRE) - Quantumzyme Corp. (OTC:QTZM), a pioneering biotechnology company specializing in computational enzyme engineering, has signed a Memorandum of Understanding (MOU) with Zummit Africa to establish a Centre of Excellence in AI for Green Chemistry. This collaboration will leverage artificial intelligence and machine learning to drive next-generation sustainable solutions in the chemical and pharmaceutical industries. This deal brings together two pioneering organizations: Quantumzyme specializes in biocatalysis and enzyme engineering to develop clean, green chemical processes. Its cutting-edge quantum mechanics, molecular modeling, and AI-driven enzyme design have led to an in-progress novel biocatalyst for Ibuprofen API production, setting a new standard for sustainable pharmaceutical manufacturing. Zummit Africa is a leading community-driven AI and data science learning platform, dedicated to empowering individuals and organizations through innovative, real-world AI applications. With expertise in machine learning and digital transformation, Zummit Africa provides the ideal technological backbone for AI-driven breakthroughs in green chemistry. The Centre of Excellence in AI for Green Chemistry will focus on: AI-driven biocatalysis - Enhancing enzyme activity, selectivity, and specificity for more efficient, eco-friendly chemical processes. Sustainable API production - Optimizing biocatalysts for pharmaceutical applications, including the greener synthesis of Ibuprofen. Data-driven molecular modeling - Using AI to predict enzyme behavior and accelerate the discovery of novel biotransformation solutions. Industry-academia collaborations - Bridging the gap between research, industry needs, and workforce development in sustainable chemistry. 'We are thrilled to partner with Zummit Africa to integrate AI into green chemistry, accelerating the transition to sustainable industrial processes,' stated Naveen Kulkarni, CEO of Quantumzyme. 'This Centre of Excellence will be a game-changer in the field, combining Quantumzyme's expertise in biocatalysis with Zummit Africa's strength in AI and machine learning.' 'Zummit Africa is committed to driving AI-powered innovation that makes a real-world impact,' continued Kulkarni. 'This partnership allows us to tackle one of the most pressing challenges of our time- sustainable chemical manufacturing- and shape the future of green chemistry.' For the most current information and updates, please visit our website at About Zummit Africa Zummit Africa is a leading AI and data science education platform, dedicated to empowering individuals and organizations with cutting-edge AI and machine learning solutions. With a focus on real-world applications, Zummit Africa is driving AI-led transformations across industries. For additional information about Zummit Africa, please visit About Quantumzyme Corp. Quantumzyme Corp. is a pioneering biotransformation company revolutionizing chemical processes through sustainable, enzyme-based solutions. Specializing in green chemistry, it harnesses quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to design high-performance biocatalysts that enhance efficiency, reduce waste, and minimize environmental impact. By integrating computational modeling with wet-lab validation, Quantumzyme delivers scalable, cost-effective biocatalysis solutions that improve industrial sustainability. Offering end-to-end enzyme development services- from discovery and engineering to process optimization and scale-up—Quantumzyme empowers its partners to adopt greener, more efficient production methods. Committed to sustainability and innovation, the company envisions a future where biotechnology drives global solutions for climate change, pollution, and resource efficiency, making eco-friendly biocatalysis the industry standard. Disclaimer The information contained in this press release is provided by Quantumzyme Corp. ('Quantumzyme') for general informational purposes only. This release may include forward-looking statements that reflect Quantumzyme's current expectations, estimates, projections, and assumptions about future events, business performance, market conditions, or technological developments. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. Forward-looking statements are based on management's beliefs and assumptions as of the date of this press release and are subject to change without notice. Quantumzyme makes no representations or warranties, express or implied, regarding the accuracy, completeness, or reliability of the information contained herein. The company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future developments, or changes in expectations, except as required by applicable law. Past performance should not be taken as an indicator of future results, and readers should not place undue reliance on any projections or expectations presented in this release. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it provide financial, investment, or legal advice. Any references to market trends, scientific advancements, or industry insights are provided for contextual purposes only and should not be interpreted as endorsements, guarantees, or definitive predictions of future developments. Readers and investors are encouraged to conduct their own due diligence and seek independent professional advice before making any investment or business decisions related to Quantumzyme or its affiliates. Media Contact: Naveen Kulkarni Chief Executive Officer Quantumzyme Corp. 15656 Bernardo Center Drive, Suite 801 San Diego, CA 92127
